Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II
Saved in:
Main Authors: | Zhi-Bin Wang, De-Hua Liao, Guang Lei, Zhao-Qian Liu, Nayiyuan Wu, Jing Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1552652/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01) -
Effect of platelet-rich plasma on angiogenic and regenerative properties in patients with critical limb ischemia
by: Hamid Tanzadehpanah, et al.
Published: (2025-03-01) -
Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01) -
Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01) -
A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment
by: Zixuan Xiong, et al.
Published: (2025-02-01)